Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
See Article on Page 2414. Potential conflict of interest: K.C. has received research support as principal investigator from the National Institutes of Health (NIH), Cirius, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, and Zydus. K.C. is a consultant for Allergan, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Deuterex, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Poxel, Novo Nordisk, and Sanofi‐Aventis. The prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) is believed to be ~70% and that of advanced fibrosis ~20%.1 Given the magnitude of the problem, there is a real sense of urgency to identify the best pharmacological approach to treat both diabetes and nonalcoholic steatohepatitis (NASH) in this population. Vitamin E is recommended for patients with biopsy‐proven NASH without diabetes,2 but did not have similar efficacy in a recent proof‐of‐concept randomized placebo‐controlled trial (RCT) in patients with T2DM.3 Regarding antidiabetic agents, there is a significant amount of data for some agents, but much more limited information for others.1 Among insulin sensitizers, whereas metformin has not shown significant benefit, pioglitazone has been incorporated into current treatment guidelines for patients with or without T2DM and biopsy‐proven NASH.2 Sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) promote glycosuria and weight loss, being considered today second‐line therapy for patients with diabetes at risk of cardiovascular disease, heart failure, or chronic kidney disease.6 Promising results have been observed for the treatment of NAFLD in animal models and in open‐label clinical trials.4 Recently, a placebo‐controlled RCT in patients with T2DM reported that canagliflozin promoted weight loss and improved hepatic insulin sensitivity and insulin secretion.7 In those with NAFLD, cangliflozin decreased intrahepatic triglycerides (IHTG) versus baseline, but this was of borderline significance when compared to placebo (−38% vs. −20%; P = 0.09). Of note, all patients received dietary advice at the onset of the trial, which likely caused the positive change in the placebo group. Reduction in IHTG did not appear to be treatment specific, but rather proportional to degree of weight loss, which was more pronounced with canagliflozin (−5.5% vs. −2.1%, respectively; P = 0.001). Patients who did not lose weight had no reduction in IHTG, but more patients on canagliflozin compared to placebo lost ≥5% of body weight and had a ≥30% reduction in IHTG (38% vs. 7%, P = 0.009). This study highlights the importance of lifestyle changes during studies in NAFLD (often even unintended by investigators) and the need for a placebo arm when investigating antidiabetic agents in NAFLD, given that past in vivo animal studies and open‐label clinical trials had suggested unique properties of SGLT2i, beyond weight loss.1 The above serves as an introduction to the role of incretin‐based therapies, the most studied group of all. In animal models of NAFLD, both glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras)8 and dipeptidyl peptidase‐4 inhibitor (DPP‐IVi)10 improve many pathways linked to steatohepatitis, although their efficacy at the clinical level has been mixed (see Tables 1 and 2). In open‐label prospective trials, sitagliptin has been found to improve plasma aminotransferases,12 IHTG,14 and liver histology.15 But negative results have also been reported with sitagliptin in open‐label studies16 and in all three placebo‐controlled trials.18 Negative studies have been also reported with liraglutide,20 but most have been positive with an improvement in hepatic steatosis (HS)22 or liver histology.29 This is usually proportional to the magnitude of weight loss, as reported for other short‐31 and long‐acting32 GLP‐1RAs. However, given the many effects of GLP‐1RAs in animal models of NAFLD, one cannot exclude mechanisms other than weight loss at play. Unfortunately, placebo‐controlled studies with liver biopsies have been rare,20 and the field still awaits the results of large RCTs with GLP‐1RAs (or DPP‐IV inhibitors) using liver histology as the primary outcome, rather than surrogate biochemical or imaging endpoints. Table 1 - Effect of Sitagliptin in NAFLD Author N Duration (Weeks) Comparator Main Study Results Weight ALT Liver Fat (IHTG*) Open‐label studies Iwasaki et al. (2011) 30 16 None Not reported ↓ n/a Ohki et al. (2012) 82 74 Liraglutide, pioglitazone Unchanged ↓ n/a Fukuhara et al. (2014) 44 52 None Not reported Unchanged n/a Asakawa et al. (2015) 62 57 None Not reported Unchanged n/a Kato et al. (2015) 20 24 Glimepiride ↓ Not reported ↓ Alam et al. (2018) 40 52 Lifestyle Unchanged ↓ ↓† Sayari et al. (2018) 138 16 Sitagliptin + synbiotic ↓ ↓ n/a RCTs Smits et al. (2016) 18 12 Liraglutide or placebo Unchanged Unchanged No change vs. placebo Cui et al. (2016) 50 24 Placebo Unchanged Unchanged No change vs. placebo Joy et al. (2017) 12 24 Placebo Unchanged Unchanged No chang
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · cited 1×
“(33) This reduction is also in agreement with the relative ~10%-20% reduction of IHTG observed in placebo arms of other controlled trials in patients with steatohepatitis (NASH).(7,34,35) Relative short duration of diabetes (~4 years) may have also promoted a better response than in previous studies, although the abso…”
ResultSelf-citationYan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
Self-citationEguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · cited 2×
“effect of liraglutide in NaFlD Author N Duration (Weeks) Comparator Main Study Results Weight ALT Liver Fat Open-label studies Ohki et al. (2012) 82 74 Sitagliptin, pioglitazone ↓ ↓ n/a Eguchi (2015) 19 24 Lifestyle ↓ ↓ ↓†”
BackgroundEffect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178 · cited 1×
“(18-20) Negative studies have been also reported with liraglutide,(20,21) but most have been positive with an improvement in hepatic steatosis (HS)(22-28) or liver histology.”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142 · cited 4×
“This was particularly true for all three placebo-controlled trials,(18-20) where the average decrease of IHTG in the placebo arms (~10%20%) was similar to the relative decrease observed with sitagliptin by Yan et al.”
BackgroundResultInfluentialOhki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139 · cited 3×
“Furthermore, Ohki et al.(22) reported that in Japanese patients with T2DM and NAFLD, sitagliptin did not modify either body weight or the aspartate to aminotransferase to platelet ratio index, which did decrease with pioglitazone or liraglutide (i.”
BackgroundInfluential
Cited by
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationKanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
Self-citationFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Self-citationLomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1997 · Cited by 354
Self-citationAdvancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01202-1 · Cited by 38
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Self-citation
Metadata
- Authors
- Cusi, K.
- Venue
- Hepatology
- Published
- 2019-05-13
- Volume
- 69
- Issue
- 6
- Pages
- 2318-2322
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2937671907
- Cited by
- 52
- References
- 15
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.